

DNA topoisomerase inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/DCD432E6992FEN.html>

Date: January 2022

Pages: 80

Price: US\$ 2,000.00 (Single User License)

ID: DCD432E6992FEN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "DNA topoisomerase inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in DNA topoisomerase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

DNA topoisomerase inhibitors Understanding

DNA topoisomerase inhibitors: Overview

Topoisomerases are essential and ubiquitous enzymes that regulate DNA topology by making temporary single- (type I) or double-strand DNA breaks (type II) [1], [2]. The DNA double helix needs to be unwound for processes such as DNA replication or transcription to take place, giving rise to the accumulation of positive supercoils ahead of transcription bubbles and replication forks, and negative supercoils or pre-catenanes behind. Topoisomerases relax supercoiled DNA and decatenate DNA to allow DNA transcription and replication to take place and are essential for genome stability

Function - DNA topoisomerases are enzymes that catalyze the alteration of DNA topology with transiently induced DNA strand breakage, essential for DNA replication.

Topoisomerases are validated cancer chemotherapy targets. Anticancer agents targeting Topoisomerase I and II have been in clinical use and proven to be highly effective, though with significant side effects. There are tremendous efforts to develop new generation of topoisomerase inhibitors.

DNA topoisomerase inhibitors - Topoisomerase inhibitors are chemical compounds that block the action of topoisomerases, which are broken into two broad subtypes: type I topoisomerases (TopI) and type II topoisomerases (TopII). Topoisomerase plays important roles in cellular reproduction and DNA organization, as they mediate the cleavage of single and double stranded DNA to relax supercoils, untangle catenanes, and condense chromosomes in eukaryotic cells. Topoisomerase inhibitors influence these essential cellular processes. Some topoisomerase inhibitors prevent topoisomerases from performing DNA strand breaks while others, deemed topoisomerase poisons, associate with topoisomerase-DNA complexes and prevent the re-ligation step of the topoisomerase mechanism. These topoisomerase-DNA-inhibitor complexes are cytotoxic agents, as the un-repaired single and double stranded DNA breaks that they cause can lead to apoptosis and cell death. Because of this ability to induce apoptosis, topoisomerase inhibitors have gained interest as therapeutics against infectious and cancerous cells.

DNA topoisomerase inhibitors Emerging Drugs Chapters

This segment of the DNA topoisomerase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

DNA topoisomerase inhibitors Emerging Drugs

DNV3837: Deinove

DNV3837 is a water soluble prodrug that is rapidly dephosphorylated after intravenous administration in humans to produce DNV3681, the active form of the drug. Its structure results from the combination of two active moieties: a fluoroquinolone that inhibits bacterial DNA gyrase to interfere with replication of the bacterial genome and an oxazolidinone that inhibits initiation of bacterial protein synthesis. The drug is in phase II of clinical development for the treatment of *Clostridium difficile* infections.

CXD 201: Celleron Therapeutics

CXD 201, a proprietary topoisomerase inhibitor, is being developed by Celleron Therapeutics (spin-off of Oxford University) and Nuance Biotech for the treatment of patients with colorectal cancer.

Further product details are provided in the report.....

DNA topoisomerase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different DNA topoisomerase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on DNA topoisomerase inhibitors

There are approx. 20+ key companies which are developing the DNA topoisomerase inhibitors. The companies which have their DNA topoisomerase inhibitors drug candidates in the most advanced stage, i.e. phase II include, Deinove.

Phases

DelveInsight's report covers around 20+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

DNA topoisomerase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

DNA topoisomerase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses DNA topoisomerase inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging DNA topoisomerase inhibitors drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence DNA topoisomerase inhibitors R&D. The therapies under development are focused on novel approaches for DNA topoisomerase inhibitors.

DNA topoisomerase inhibitors Report Insights

DNA topoisomerase inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

DNA topoisomerase inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing DNA topoisomerase inhibitors drugs?

How many DNA topoisomerase inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for DNA topoisomerase inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the DNA topoisomerase inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for DNA topoisomerase inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Deinove

Celleron Therapeutics

BioNumerik Pharmaceuticals

Shasqi

Mundipharma

Oasmia Pharmaceutical

Gibson Oncology

GlaxoSmithKline

Fujifilm Pharmaceuticals USA

Ascelia Pharma

Nektar Therapeutics

Luye Pharma

Targeted Therapy Technologies

Athenex

Cao Pharmaceuticals

Intezyne

RedxPharma

Key Products

DNV3837

CXD 201

Cositecan

SQ 3370

Etoposide toniribate

Research programme: cancer therapeutics

Indotecan

Gepotidacin

Topotecan liposomal

Irinotecan oral

Etirinotecan pegol

Irinotecan hydrochloride liposomal

Episcleral topotecan

Encequidar/topotecan

CZ 48

IT 141

Contents

Introduction

Executive Summary

DNA topoisomerase inhibitors: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

DNA topoisomerase inhibitors – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

DNA topoisomerase inhibitors companies' collaborations, Licensing, Acquisition -Deal Value Trends

DNA topoisomerase inhibitors Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Pre-registration)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

DNV3837 : Deinove

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

CXD 201: Celleron Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

DNA topoisomerase inhibitors Key Companies

DNA topoisomerase inhibitors Key Products

DNA topoisomerase inhibitors- Unmet Needs

DNA topoisomerase inhibitors- Market Drivers and Barriers

DNA topoisomerase inhibitors- Future Perspectives and Conclusion

DNA topoisomerase inhibitors Analyst Views

DNA topoisomerase inhibitors Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for DNA topoisomerase inhibitors

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for DNA topoisomerase inhibitors
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: DNA topoisomerase inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/DCD432E6992FEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DCD432E6992FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970